Mixed Flashcards
1
Q
RECOURSE Trial
A
2015 NEJM Mayer – Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer - PH - PMID:25970050 -
Phase 3; International;
1-OS;
800 pts with Refractory disease randomized 2:1
TAS-102 VS Placebo; Median OS 7.1 m VS 5.3 m, p
2
Q
ELOQUENT-2 Trial
A
ELOQUENT-2 Trial - 2015 NEJM Lonial – Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.pdf - PH - Phase 3; Randomized 321 pts Elotuzumab + Rd VS 325 pts Rd alone; 1-PFS/ORR; @median followup of 24.5 m, 1-yr PFS 68% VS 57%, 2-yr PFS 41% VS 27%; Median PFS 19.4 m VS 14.9 m, HR 0.70, p
